Fingolimod Hydrochloride

interferon beta 1 ; Homo sapiens

16 Article(s)
Pub. Year
#Total Relationships
1 35020157 Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry. 2022 Mar 1
2 33597189 Interferon-β Is Less Effective Than Other Drugs in Controlling the Rate of Retinal Ganglion Cell Loss in MS. 2021 May 1
3 32414131 CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis. 2020 May 13 1
4 33189062 Correlation between IL-31 and sCD40L plasma levels in Fingolimod-treated patients with Relapsing-Remitting Multiple Sclerosis (RRMS). 2020 Nov 5 1
5 30644981 Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. 2019 Jan 15 1
6 29497558 Risk factors for fingolimod-induced lymphopenia in multiple sclerosis. 2018 Jan-Mar 1
7 29521113 Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience. 2018 May 1
8 29974307 Brain volume loss is present in Japanese multiple sclerosis patients with no evidence of disease activity. 2018 Oct 1
9 27857690 Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab. 2016 1
10 25546031 Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. 2015 Mar 1
11 25876471 Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. 2014 May 1
12 25876473 Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). 2014 May 2
13 23738997 Fingolimod for the treatment of relapsing multiple sclerosis. 2013 Jun 1
14 24139422 Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States. 2013 Oct 1
15 22494956 Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. 2012 May 1
16 21751747 Fingolimod. 2011 Jul-Aug 1